• **Full Name:** Minsun Jung

• **Current Position & Affiliation:** Assistant professor, Department of Pathology, Yonsei University College of Medicine

• **Country:** Republic of Korea

• **Educational Background:**

- Ph.D., Department of Pathology, Seoul National University College of Medicine, Seoul, Republic of Korea. 2020
- M.S., Department of Pathology, Kangwon National University College of Medicine, Gangwon-do, Republic of Korea. 2016
- B.M., Korea University, Seoul, Republic of Korea. 2012

• **Professional Experience:**

- Assistant professor, Department of Pathology, Yonsei University College of Medicine, Seoul, Republic of Korea. 2023–
- Clinical assistant professor, Department of Pathology, Yonsei University College of Medicine, Seoul, Republic of Korea. 2021–2023
- Fellow, Department of Pathology, Seoul National University Hospital, Seoul, Republic of Korea. 2020–2021
- Resident, Department of Pathology, Seoul National University Hospital, Seoul, Republic of Korea. 2016–2020

• **Professional Organizations:**

• **Main Scientific Publications:**

1. Kim B, Jung M, Moon KC, et al. Quantitative proteomics identifies TUBB6 as a biomarker of muscle-invasion and poor prognosis in bladder cancer. Int J Cancer. 2023

2. Jung M, Lee JA, Yoo SY, et al. Intratumoral spatial heterogeneity of tumor-infiltrating lymphocytes is a significant factor for precisely stratifying prognostic immune subgroups of microsatellite instability-high colorectal carcinomas. Mod Pathol. 2022

3. Jung M, Jin MS, Kim C, et al. Artificial intelligence system shows performance at the level of uropathologists for the detection and grading of prostate cancer in core needle biopsy: an independent external validation study. Mod Pathol. 2022

4. Jung M, Lee H, Moon KC. Morphometric analysis of lysosomes in the renal tubule in monoclonal gammopathy using transmission electron microscopy: “Mottled Appearance” and beyond. Microsc Microanal. 2022

5. Jung M, Lee KM, Im Y, et al. Nicotinamide (niacin) supplement increases lipid metabolism and ROS-induced energy disruption in triple-negative breast cancer: potential for drug repositioning as an anti-tumor agent. Mol Oncol. 2022